EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Head and Neck Cancer

Lara A Dunn, Alan L Ho, David G Pfister

JAMA · 10.02.2026 · 335 (6) · 531

DOI: 10.1001/jama.2025.21733 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 10.02.2026. Verfasst von Lara A Dunn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Neoplasms, Unknown Primary, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 89 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Head and neck cancer, which arises in the lining or mucosa of the upper aerodigestive tract, specifically the oral cavity, oropharynx, larynx, hypopharynx, and paranasal sinuses, is the seventh most common cancer worldwide. In 2024, approximately 71 110 individuals in the US were diagnosed with head and neck cancer, and it accounted for 16 110 deaths. Observations Approximately 90% of head and neck cancers are squamous cell carcinomas. Worldwide, tobacco and alcohol use are the most prevalent risk factors. In the US and Europe, 60% to 70% of newly diagnosed oropharynx cancers (a subset of head and neck cancers) are caused by human papillomavirus (HPV) infection. At presentation, approximately 30% of patients with head and neck cancer have early-stage or localized disease (tumor <4 cm without regional lymph nodes involvement), 60% have locoregionally advanced disease (tumor ≥4 cm with local invasion and/or regional lymphadenopathy) and 10% have metastatic disease. Up to 10% of oropharynx squamous cell carcinomas present as squamous cell carcinomas of unknown primary. Standard treatment for localized head and neck cancer is surgery or radiotherapy, which are each associated with a 5-year overall survival rate of 70% to 90%. For locoregionally advanced head and neck cancer, multimodality treatment includes surgery followed by postoperative radiation with or without chemotherapy or concomitant chemotherapy (with cisplatin as the preferred agent), and radiation with surgery is reserved for persistent or recurrent disease. With these treatments for locoregionally advanced head and neck cancer, 5-year overall survival rates are 25% to 60% and more than 80% for HPV-associated oropharynx cancer. Choice of treatment for locoregionally advanced head and neck cancer should involve shared decision-making and consideration of effects on speech and swallow function and appearance. First-line treatment for patients with incurable locoregional recurrences or distant metastatic disease is immunotherapy with programmed death ligand-1 inhibition (ie, pembrolizumab) alone or in combination with platinum-doublet chemotherapy. With treatment, patients with incurable locoregional recurrences or distant metastatic disease have a median survival of 12 to 15 months, and 5-year survival rates are less than 20%. Conclusions and Relevance Head and neck cancer is the seventh most common cancer worldwide. In the US and Europe, 60% to 70% of incident oropharynx cancers are associated with HPV infection. Standard treatment for localized head and neck cancer is surgery or radiotherapy. Locoregionally advanced disease is treated with surgery followed by radiation with or without chemotherapy or concurrent chemoradiation. First-line treatment for advanced disease is immunotherapy alone or with chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckNeoplasms, Unknown PrimaryNeoplasm Recurrence, LocalHumansCombined Modality TherapyPapillomavirus InfectionsRisk FactorsTobacco Use DisorderAlcohol DrinkingNeoplasm StagingRadiotherapy, AdjuvantChemotherapy, AdjuvantSurvival RateImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy Protocols

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Weill Cornell Medical College, New York, New York.

Zitieren

APA

Dunn, L. A., Ho, A. L., & Pfister, D. G. (2026). Head and Neck Cancer. JAMA, 335(6), 531. https://doi.org/10.1001/jama.2025.21733

Vancouver

Dunn LA, Ho AL, Pfister DG. Head and Neck Cancer. JAMA. 2026;335(6):531. doi:10.1001/jama.2025.21733

BibTeX
@article{Dunn2026,
  author = {Dunn, Lara A and Ho, Alan L and Pfister, David G},
  title = {Head and Neck Cancer},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {6},
  pages = {531},
  doi = {10.1001/jama.2025.21733}
}
Kostenlos starten →